|
TTC39B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.958490E-03 |
| Normal-vs-Stage3 |
3.29281046873575E-12 |
| Normal-vs-Stage4 |
5.50420000022811E-07 |
| Stage1-vs-Stage2 |
1.144360E-02 |
| Stage1-vs-Stage3 |
7.387200E-01 |
| Stage1-vs-Stage4 |
3.262000E-01 |
| Stage2-vs-Stage3 |
3.256400E-02 |
| Stage2-vs-Stage4 |
9.821300E-03 |
| Stage3-vs-Stage4 |
2.689600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62458935193399E-12 |
| Normal-vs-AfricanAmerican |
7.71500000000813E-05 |
| Normal-vs-Asian |
4.09629999920114E-08 |
| Caucasian-vs-AfricanAmerican |
1.400560E-01 |
| Caucasian-vs-Asian |
7.776000E-01 |
| AfricanAmerican-vs-Asian |
1.796790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.85849122150239E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.894500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(61-80Yrs) |
1.61419999589185E-08 |
| Normal-vs-Age(81-100Yrs) |
9.646200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.619900E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.048300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.399300E-03 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.703200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.433000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.551900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.637000E-03 |
| Classical-VS-Follicular |
3.21997983832034E-12 |
| Classical-VS-Other |
8.708800E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
2.10860000016133E-07 |
| Tall-VS-Other |
1.440020E-01 |
| Tall-VS-Normal |
3.37890004864505E-09 |
| Follicular-VS-Other |
1.382270E-02 |
| Follicular-VS-Normal |
2.002600E-03 |
| Other-VS-Normal |
6.219400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.6278089987054E-12 |
| Normal-vs-N1 |
3.41799999969972E-07 |
| N0-vs-N1 |
1.952230E-02 |
|
|
